Affymax Receives $5 Million Milestone Payment On Initiation Of Phase 3 Clinical Trials For Hematide™ In Japan
Source: Medical News Today
Friday 12th March, 2010
Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to ... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
